Interní Med. 2007; 9(12): 571-574

Kontrola hlavních rizikových faktorů provázejících hypertenzi

prof. MUDr. Jiří Widimský DrSc., FESC1, doc. MUDr. Miroslav Souček CSc2, MUDr. Martina Sachová3
1 II. interní klinika LF UK a Fakultní nemocnice, Hradec Králové
2 II. interní klinika FN u sv. Anny LF MU, Brno
3 Servier s. r. o., Praha

Nálezy práce ukazují špatnou kontrolu hypertenze, hypercholesterolemie a diabetu v klinické praxi praktických lékařů. Navíc bylo zjištěno, že čím byla kontrola hypertenze horší, tím byla vyšší glykemie nalačno a tím byla také vyšší koncentrace celkového cholesterolu.

Published: January 20, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Widimský J, Souček M, Sachová M. Kontrola hlavních rizikových faktorů provázejících hypertenzi. Interní Med. 2007;9(12):571-574.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R, Horký K, Widimský J sr, et al za Českou společnost pro hypertenzi. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitřní lék 2004; 50: 709-722.
    2. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393. Go to original source... Go to PubMed...
    3. Gress TW, Nieto FJ, Shahar E, et al, for the atherosclerosis risc in communities study. Hypertension and antihypertensive therapy as risk factors for type-2 diabetes mellitus. N Engl J Med 2000; 342: 905-912. Go to original source... Go to PubMed...
    4. Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-1053. Go to original source... Go to PubMed...
    5. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Metabolic precursors of hypertension. The San Antonio Heart Study. Arch Intern Med 1996; 156: 1994-2001. Go to original source...
    6. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. Go to original source... Go to PubMed...
    7. Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494. Go to original source... Go to PubMed...
    8. Knowler WC, Sartor G, Melander A, Schersten B. Glucose tolerance and mortality, including a substudy of tolbutamide treatment. Diabetologia 1997; 40: 680-686. Go to original source... Go to PubMed...
    9. Lewington S, MacMahon S. Blood pressure, cholesterol and common cause of death: a review. Prospective studies collaboration. Am J Hypertens 1999; 12: 96S-98S. Go to original source... Go to PubMed...
    10. Mancia G, Facchetti R, Bombelli M, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension 2005; 45: 1072-1077. Go to original source... Go to PubMed...
    11. Sever PS, Dahlöf B, Poulter NR, et al, for the ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-1158. Go to original source... Go to PubMed...
    12. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444. Go to original source... Go to PubMed...
    13. Škrha J. Diabetes mellitus 2002 v České republice - Epidemiologická studie. Diabet Metabol Endokrin Výž 2005; 8: 5-12.
    14. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986. Go to original source... Go to PubMed...
    15. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in Type 2 diabetes. UKPDS38. Br Med J 1998; 317: 703-713. Go to original source... Go to PubMed...
    16. Widimský J, Sachová M, Souček M, Lánská V. Vysoká prevalence a špatná kontrola hypertenze v ordinacích praktických lékařů. Vnitřní Lék. 2005; 51: 1087-1095.
    17. Widimský J Sr, Soucek M, Sachova M, Lanska V. High prevalence and poor control of hypertension in the primary care of the Czech republic. J Hypertens 2005; 23 (Suppl. 3): S30-31.
    18. Widimský J, Souček M, Sachová M, Lánská V. Hypertenze a diabetes mellitus v ordinacích praktických lékařů. Výskyt hypertenze a její kontrola. Cor Vasa 2005; 47: 127-134.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.